Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

37results about How to "Strong target specificity" patented technology

Biosensor based on aptamer and manufacturing method and application thereof

ActiveCN103529113AImprove electrochemical activitySimplify the analysis processMaterial electrochemical variablesAptamerEpoxy
The invention discloses a biosensor based on an aptamer and a manufacturing method and application thereof and belongs to the field of biochemical technique. According to the biosensor based on the aptamer, n-octadecyl mercaptan is automatically assembled on a gold film, the n-octadecyl mercaptan is combined with carboxyl group graphene oxide through intermolecular force, activating treatment is carried out on the carboxyl group graphene oxide to enable carboxyl to be converted into an active ester group, and an amido bond is formed through the active ester group and amino acid on molecule of the aptamer to enable the aptamer to be fixed on the surface of the carboxyl group graphene oxide. According to the biosensor based on the aptamer, the electrochemical activity is good, the aptamer can be well fixed, and the biosensor can be used for detection of various kinds of target protein and can be applied to the fields such as biomedicine, food safety and environmental monitoring. The manufacturing method of the biosensor based on the aptamer is simple and easy to operate. Due to the fact that hydroxyl and epoxy group which are on the graphene oxide are converted into the carboxyl due to the adoption of NaOH and ClCH2COONa, the COOH functional group content is high, the good electrochemical activity is achieved, and the aptamer can be well fixed.
Owner:ZHENGZHOU UNIVERSITY OF LIGHT INDUSTRY

Construction method of LRFFT1 cells

ActiveCN110093376AStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsEpitopeExpression gene
The present invention discloses a construction method of LRFFT1 cells. The construction method of the LRFFT1 cells comprises the following steps: ctDNA sequencing of human peripheral blood or whole exon sequencing of tumor tissues is conducted to screen out mutation sites for antigen epitope prediction, and a mutant polypeptide expression gene sequence is ligated and synthesized; simultaneously alentiviral vector is constructed, lentiviruses are packaged, the packaged lentiviruses transfect APC cells, modification of specific LV cells is completed, the APC cells are co-cultured with PBMC isolated from peripheral blood in vitro, effective peptides are screened out, and ordinary T cells are transformed into RFF cells with a more precise killing ability by a second impact of a precise and effective peptide stimulation; then a TCR-T technology principle is used to conduct modification; and the modified T cells are then subjected to a gene-editing technology to conduct knocking out of immunosuppressive targets, the T cells with the specific killing ability is precisely protected from in vivo inhibition, the killing ability of the T cells on tumor cells is improved, and the LRFFT1 cellsmore combining attack and defense are obtained.
Owner:BEIJING DCTY BIOTECH CO LTD

AFFT2 cell

ActiveCN109136284AStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsSignalling moleculesTumor antigen
The invention belongs to the field of biotechnology and particularly relates to an AFFT2 cell and a preparation method of the AFFT2 cell. The cell is transformed through the TCR-T technology, the transformed T cell is closed in vitro through an inhibitory signal molecular antibody drug, so that the anti-tumor capability of the T cell is improved effectively, and among the cell transformed throughthe AFFT2 scheme, the proportion of the specific T cell capable of recognizing a tumor antigen is more than 70%.
Owner:BEIJING DCTY BIOTECH CO LTD

MRFFT1 cell

ActiveCN109136278AStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsEpitopePeripheral blood mononuclear cell
The invention relates to an MRFFT1 cell and a preparation method of the MRFFT1 cell, a mutation polypeptide is screened through the predication of an epitope, the sequence of an expression gene of themutation polypeptide is connected and synthesized; meanwhile, an MVA virus vector is constructed, an MVA virus is packaged, an APC (Antigen Presenting Cell) is transfected, the transformation of a specific MV cell is finished, the APC is cultured in vitro together with a PBMC (Peripheral Blood Mononuclear Cell) separated from the peripheral blood, the effective polypeptide is screened, a common Tcell is transformed into an RFF cell having more accurate lethality through the second impact stimulated by the accurate effective polypeptide; the transformation is conducted through the TCR-T technical principle; an immunosuppressive target of the transformed T cell is knocked off through the gene editing technology, the specific lethal T cell is protected accurately against in-vivo suppression, and the lethality of the T cell on a tumor cell is improved.
Owner:BEIJING DCTY BIOTECH CO LTD +1

LRFFT2 cell

ActiveCN109679917AStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyHydrolasesT cellIn vivo
The invention discloses an LRFFT2 cell. According to the LRFFT2 cell, human peripheral blood is used for carrying out ctDNA sequencing or carrying out whole exome sequencing on tumor tissue, mutationsites are screened out for antigen epitope prediction, and mutant polypeptide expression gene sequences are connected and synthesized; meanwhile, a lentivirus vector is constructed, lentivirus is packaged, an APC cell is transfected, the modification of a specific LV cell is completed, co-culture is carried out with a PBMC separated from the peripheral blood in vitro, effective polypeptide is screened out, and the second impact of stimulation of the effective polypeptide is accurate, so that a common T cell is transformed into an RFF cell with more accurate killing capability; transformation is carried out by utilizing a TCR-T technical principle; and immunosuppressive signal sealing is carried out on the transformed T cell in vitro by using an antibody drug, so that the specific killing Tcell is accurately protected from in-vivo suppression, and the killing force of the T cell on a tumor cell is improved, and therefore the LRFFT2 cell with better attack and defense functions is obtained. The LRFFT2 cell can be widely applied to individualized accurate treatment of solid tumors.
Owner:BEIJING DCTY BIOTECH CO LTD +1

Construction method of HAFFT1 cells

ActiveCN110157745AStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsCancer cellT cell
The invention belongs to the field of biotechnology, and particularly relates to a construction method of HAFFT1 cells. According to the method, small-molecule-modified polypeptide-stimulated cells are modified through a TCR-T technology. The modified T cells are subjected to immunosuppressive target pot knockout, specific killer T cells are accurately protected and prevented from inhibition in vivo, and the killing ability of the T cells to cancer cells is improved. The proportion of specific T cells (TCR+) recognizing tumor antigens is more than 80% in the HAFFT1 modified cells.
Owner:BEIJING DCTY BIOTECH CO LTD +1

A lrfft1 cell

ActiveCN109294997BStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsAntigen epitopeAntigen
CtDNA sequencing of human-derived peripheral blood or whole exon sequencing of tumor tissues is carried out to screen a mutation site for antigen epitope prediction, and the mutation site undergoes antigen epitope prediction to ligate and synthesize a mutant polypeptide expression gene sequence; construction of a lentiviral vector and packaging of the lentivirus are simultaneously carried out, anAPC cell is transferred, the transformation of a specific LV cell is completed, an in vitro PBMC and a PBMC isolated from peripheral blood are co-cultured, an effective peptide is screened, and an ordinary T cell is transformed through accurate and effective peptide stimulated secondary impact to form an RFF cell having an accurate killing capability; transformation is carried out by using a TCR-Ttechnology principle; and the modified T cell undergoes immunosuppressive target knockout by using a gene editing technology, so a specific killer T cell is accurately protected from being inhibitedin vivo, the lethality of the T cell on tumor cells is improved, and the offensive and defensive LRFFT1 cell is obtained.
Owner:BEIJING DCTY BIOTECH CO LTD

LRFF cell construction method

InactiveCN109136268AStrong target specificityLess prone to off-target effectsGenetically modified cellsBlood/immune system cellsPeripheral blood mononuclear cellWilms' tumor
The invention provides an LRFF cell construction method, human peripheral blood is used to sequence ctDNA or a whole exome of a tumor tissue, a mutation site is screened to predicate an epitope, and the sequence of an expression gene of a mutation polypeptide is connected and synthesized; meanwhile, a lentiviral vector is constructed, a lentivirus is packaged, an APC (Antigen Presenting Cell) is transfected to finish the transformation of a specific LV cell, the APC is cultured in vitro together with a PBMC (Peripheral Blood Mononuclear Cell) separated from the peripheral blood, the effectiveaccurate polypeptide is screened, a common T cell is transformed into an LRFF cell having more accurate lethality through the second impact stimulated by the accurate polypeptide; and the lethality ofthe T cell on a tumor cell is improved. The provided LRFF cell is widely applied to the individualized accurate treatment of a solid tumor.
Owner:BEIJING DCTY BIOTECH CO LTD

Construction method of MRFFT2 cells

ActiveCN110093375AStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsIrritationIn vivo
The invention relates to a construction method of MRFFT2 cells. an epitope is use for forecasting and screening out mutation polypeptide, and an expression gene sequence of the mutation polypeptide is connected and synthesized; besides, an MVA virus vector is constructed, an MVA virus is packaged, transfection on APCs (antigen presenting cells) is performed, the reformation of a specific MV cellis completed, the APCs and PBMCs separated from peripheral blood are co-cultured in vitro, and effective polypeptide is screened; through second impact with accurate effective polypeptide irritation,ordinary T cells are reformed into RFF cells having pinpoint killing capacity; and then through a TCR-T technique principle, reformation is performed, the reformed T cells are subjected to immunosuppression signal enclosing through an antibody medicine in vitro, specific killer T cells are accurately protected from in vivo restraint, and the lethality of the T cells on tumor cells is increased.
Owner:BEIJING DCTY BIOTECH CO LTD

A kind of construction method of mrfft1 cell

ActiveCN110093374BStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsAntigen epitopeAntigen
The invention relates to a method for constructing MRFFT1 cells. The method comprises the following steps of: screening out a mutant polypeptide through antigen epitope prediction, connecting and synthesizing a mutant polypeptide expression gene sequence; and meanwhile, constructing an MVA virus vector, packaging MVA virus, transfecting APC cells, completing the modification of specific MV cells,co-culturing PBMC separated from peripheral blood with the modified specific MV cells in vitro, screening out effective polypeptide, modifying common T cells into RFF cells with more accurate killingcapacity through the second impact of accurate effective polypeptide stimulation, performing modification with a TCR-T technology principle, and knocking out immunosuppressive target of the modified Tcells by using a gene editing technology. The method accurately protects specific killing T cells from in-vivo inhibition, and improves the killing ability of T cells to tumor cells.
Owner:BEIJING DCTY BIOTECH CO LTD +1

Construction method of AFF cells

InactiveCN110093316AStrong target specificityLess prone to off-target effectsBlood/immune system cellsCell culture active agentsEpitopeExon
The invention belongs to the technical field of biology, and particularly relates to a construction method of AFF cells. The construction method of the AFF cells comprises the following main steps: 1)drawing peripheral blood of a patient, performing ctDNA exon sequencing, or performing full exon sequencing on tumor tissues, screening out mutation sites, performing epitope prediction, and synthesizing mutant polypeptides; and 2) preparing immortalized DC by using the peripheral blood, loading the immortalized DC with the mutant polypeptides, and co-incubating the immortalized DC with PBMC to obtain the AFF cells.
Owner:BEIJING DCTY BIOTECH CO LTD

A preparation method of microfluidic chip embedded with oriented nanofiber membrane

The invention relates to a production method of an oriented nanofiber membrane-embedded micro-fluidic chip. The method comprises the following steps: carrying out electrostatic spinning and steam crosslinking on a PEI / PVA spinning solution to obtain an oriented PEI / PVA nanofiber membrane; modifying the surface of the oriented PEI / PVA nanofiber membrane with zwitterionic MPC and a targeting ligand Cys-PEG-FA to obtain PEI / PVA-PMPC-FA; and carrying out plasma bonding on the PEI / PVA-PMPC-FA and a herringbone PDMS micro-fluidic chip to obtain the oriented nanofiber membrane-embedded micro-fluidic chip which can be used for sorting circulating tumor cells. The oriented nanofiber membrane-embedded micro-fluidic chip is simple to operate, can rapidly realize the highly-pure capture and rapid release of the circulating tumor cells in blood, endows the nanofiber membrane with excellent anti-protein and anti-blood cell adhesion performances through amphion modification to improve the cell capture purity, and reduces the non-specific adhesion of blood cells through the oriented nanofiber membrane in order to further improve the capture purity, so the oriented nanofiber membrane-embedded micro-fluidic chip has a wide application prospect.
Owner:DONGHUA UNIV

Constructing method of AFFT1 cells

ActiveCN110408657AIncrease lethalityStrong target specificityImmunoglobulin superfamilyGenetically modified cellsIn vivoT cell
The invention relates to a preparation method of AFFT1 cells. RFF cells are transformed through a TCR-T technical principle, then immunosuppression target spots of transformed T cells are knocked outthrough a gene editing technology, thus the specific cytotoxic T cells are precisely protected against being inhibited in vivo, and the lethality of the T cells on tumor cells is improved.
Owner:BEIJING DCTY BIOTECH CO LTD

Construction method of AFFT2 cells

ActiveCN110093373AStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsSignalling moleculesTumor antigen
The invention belongs to the field of a biological technology, and particularly relates to a construction method of AFFT2 cells. According to the method, the cells are reformed by a TCR-T technique, and the reformed T cells are subjected to in vitro sealing by using inhibition signal molecule antibody medicines, so that the antitumor capacity of the T cells can be effectively improved. For cells reformed by an AFFT2 scheme, the proportion for distinguishing the specific T cells of tumor antigen is 70% or above.
Owner:BEIJING DCTY BIOTECH CO LTD

LRFFT2 cell construction method

InactiveCN109136277APrecision killing capabilityIncrease lethalityImmunoglobulin superfamilyGenetically modified cellsPeripheral blood mononuclear cellIn vivo
The invention provides an LRFFT2 cell construction method, human peripheral blood is used to sequence ctDNA or a whole exome of a tumor tissue, a mutation site is screened to predicate an epitope, andthe sequence of an expression gene of a mutation polypeptide is connected and synthesized; meanwhile, a lentiviral vector is constructed, a lentivirus is packaged, an APC (Antigen Presenting Cell) istransfected to finish the transformation of a specific LV cell, the APC is cultured in vitro together with a PBMC (Peripheral Blood Mononuclear Cell) separated from the peripheral blood, the effective polypeptide is screened, a common T cell is transformed into an RFF cell having more accurate lethality through the second impact stimulated by the accurate effective polypeptide; the transformationis conducted through the TCR-T technical principle; an immunosuppressive signal of the transformed T cell is closed in vitro by using an antibody drug, the specific lethal T cell is protected accurately against in-vivo suppression, the lethality of the T cell on a tumor cell is improved, and a more offensive and defensive LRFFT2 cell is obtained. The LRFFT2 cell is widely applied to the individualized accurate treatment of a solid tumor.
Owner:BEIJING DCTY BIOTECH CO LTD +1

A kind of construction method of lrfft1 cell

ActiveCN110093376BStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsAntigen epitopeAntigen
The present invention discloses a construction method of LRFFT1 cells. The construction method of the LRFFT1 cells comprises the following steps: ctDNA sequencing of human peripheral blood or whole exon sequencing of tumor tissues is conducted to screen out mutation sites for antigen epitope prediction, and a mutant polypeptide expression gene sequence is ligated and synthesized; simultaneously alentiviral vector is constructed, lentiviruses are packaged, the packaged lentiviruses transfect APC cells, modification of specific LV cells is completed, the APC cells are co-cultured with PBMC isolated from peripheral blood in vitro, effective peptides are screened out, and ordinary T cells are transformed into RFF cells with a more precise killing ability by a second impact of a precise and effective peptide stimulation; then a TCR-T technology principle is used to conduct modification; and the modified T cells are then subjected to a gene-editing technology to conduct knocking out of immunosuppressive targets, the T cells with the specific killing ability is precisely protected from in vivo inhibition, the killing ability of the T cells on tumor cells is improved, and the LRFFT1 cellsmore combining attack and defense are obtained.
Owner:BEIJING DCTY BIOTECH CO LTD

LRFFT1 cell construction method

InactiveCN109136280AIncrease lethalityStrong target specificityImmunoglobulin superfamilyGenetically modified cellsImmunosuppressionExome
The invention provides an LRFFT1 cell construction method, human peripheral blood is used to sequence ctDNA or a whole exome of a tumor tissue, a mutation site is screened to predicate an epitope, andthe sequence of an expression gene of a mutation polypeptide is connected and synthesized; meanwhile, a lentiviral vector is constructed, a lentivirus is packaged, an APC (Antigen Presenting Cell) istransfected to finish the transformation of a specific LV cell, the APC is cultured in vitro together with a PBMC (Peripheral Blood Mononuclear Cell) separated from the peripheral blood, the effective polypeptide is screened, a common T cell is transformed into an RFF cell having more accurate lethality through the second impact stimulated by the accurate effective polypeptide; the transformationis conducted through the TCR-T technical principle; an immunosuppressive target of the transformed T cell is then knocked off through the gene editing technology, the specific lethal T cell is protected accurately against in-vivo suppression, the lethality of the T cell on a tumor cell is improved, and a more offensive and defensive LRFFT1 cell is obtained.
Owner:BEIJING DCTY BIOTECH CO LTD

Acetyltransferase ARD1 inhibitor D753-0266 and application thereof in colorectal cancer treatment

The invention discloses an acetyltransferase ARD1 inhibitor D753-0266 and application of the acetyltransferase ARD1 inhibitor D753-0266 in colorectal cancer treatment, and relates to the technical field of biological medicines. Through molecular dynamics simulation and binding energy calculation, it is found that the binding energy of D753-0266 and NAA10 can reach-68.12 kcal / mol. In-vitro experiments show that D753-0266 can be directly combined with and stabilize ARD1 protein, down-regulate the expression level of the ARD1 protein, inhibit colorectal cancer cell proliferation in a dose-dependent manner, and remarkably inhibit cell migration and clone formation capability at the same time. In-vivo experiments show that the D753-0266 can effectively inhibit tumor growth in a mouse transplantation tumor model and has good tolerance. The inhibitor fills up the research blank in the field of targeting ARD1, can be used for preparing colorectal cancer treatment drugs, and has high specificity and clinical transformation potential.
Owner:KUNMING MEDICAL UNIVERSITY

A mrfft2 cell

ActiveCN109295097BStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsAntigen epitopeAntigen
The invention relates to an MRFFT2 cell and a preparation method thereof. Mutant polypeptides are screened by antigen epitope prediction, and are ligated to synthesize a mutant polypeptide expressiongene sequence; an MVA virus vector is constructed, an MVA virus is packaged, an APC cell is transferred, the transformation of a specific MV cell is completed, in vitro PBMC and a PBMC isolated from peripheral blood are co-cultured, an effective peptide is screened, an ordinary T cell is transformed through accurate and effective peptide stimulated secondary impact to form an RFF cell having an accurate killing capability, transformation is carried out by using a TCR-T technology principle, the modified T cell undergoes immunosuppressive signal closing by using antibody drug in vitro, so a specific killer T cell is accurately protected from being inhibited in vivo, and the lethality of the T cell on tumor cells is improved.
Owner:BEIJING DCTY BIOTECH CO LTD

A kind of construction method of afft1 cell

ActiveCN110408657BStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsT cellTumor cells
The invention relates to a preparation method of AFFT1 cells. RFF cells are transformed through a TCR-T technical principle, then immunosuppression target spots of transformed T cells are knocked outthrough a gene editing technology, thus the specific cytotoxic T cells are precisely protected against being inhibited in vivo, and the lethality of the T cells on tumor cells is improved.
Owner:BEIJING DCTY BIOTECH CO LTD

A hafft1 cell

ActiveCN109295106BStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyHydrolasesTumor antigenT cell
The invention belongs to the field of biotechnology, and in particular relates to a HAFFT1 cell and a preparation method thereof. The cells are modified with TCR-T technology, and the modified T cells are then knocked out of immunosuppressive targets, which precisely protects the specific killer T cells from inhibition in vivo and improves the lethality of T cells against tumor cells . The proportion of specific T cells (TCR+) that recognize tumor antigens in the cells transformed by the HAFFT1 program is over 80%.
Owner:BEIJING DCTY BIOTECH CO LTD +1

A kind of construction method of afft2 cell

ActiveCN110093373BStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsAntiendomysial antibodiesSignalling molecules
The invention belongs to the field of biotechnology, and in particular relates to a method for constructing AFFT2 cells. This method transforms cells with TCR-T technology, and the transformed T cells are blocked in vitro with inhibitory signal molecule antibody drugs, thereby effectively improving the anti-tumor ability of T cells. Cells transformed by the AFFT2 program can recognize tumor antigens The proportion of specific T cells is above 70%.
Owner:BEIJING DCTY BIOTECH CO LTD

MRFFT2 cell construction method

InactiveCN109136279APrecision killing capabilityStrong target specificityImmunoglobulin superfamilyGenetically modified cellsPeripheral blood mononuclear cellIn vivo
The invention relates to an MRFFT2 cell construction method, a mutation polypeptide is screened through the predication of an epitope, the sequence of an expression gene of the mutation polypeptide isconnected and synthesized; meanwhile, an MVA virus vector is constructed, an MVA virus is packaged, an APC (Antigen Presenting Cell) is transfected, the transformation of a specific MV cell is finished, the APC is cultured in vitro together with a PBMC (Peripheral Blood Mononuclear Cell) separated from the peripheral blood, the effective polypeptide is screened, a common T cell is transformed into an RFF cell having more accurate lethality through the second impact stimulated by the accurate effective polypeptide; the transformation is conducted through the TCR-T technical principle; an immunosuppressive signal of the transformed T cell is closed by using an antibody drug in vitro, the specific lethal T cell is protected accurately against in-vivo suppression, and the lethality of the T cell on a tumor cell is improved.
Owner:BEIJING DCTY BIOTECH CO LTD

Preparation method of novel nano preparation capable of treating brain glioma

InactiveCN113384707AStrong target specificityGood for active modificationOrganic active ingredientsPharmaceutical non-active ingredientsReceptorPolyethylene glycol
The invention discloses a preparation method of a novel nano preparation capable of treating brain glioma. The preparation method of the novel nano preparation capable of treating the brain glioma comprises the following steps of synthesizing an LAT1 targeting material, specifically, taking polyethylene glycol monostearate as a raw material, and synthesizing the LAT1 targeted material by connecting glutamic acid through esterification reaction; preparing a brain-targeted liposome based on LAT1, and modifying the surface of the liposome with an LAT1 targeted material to prepare the temozolomide entrapped liposome with a brain-targeted function. According to the preparation method of the novel nano preparation capable of treating the brain glioma, the LAT1 has high expression in brain cells and a blood brain barrier, and the targeting specificity is relatively strong; different from a conventional immune antigen protein receptor, a synthesized novel LAT1 active targeted material is characterized in that a substrate of the LAT1 is amino acid organic small molecules which are beneficial to active modification and have no immunogenicity; a good foundation is provided for an active targeting preparation of the LAT1; an active targeted liposome entraps temozolomide first-line treatment medicine, the unique advantage of active medicine loading can be achieved by applying the liposome, temozolomide molecules are wrapped in an inner water phase, the stability is good, and the entrapment efficiency is high.
Owner:高州市人民医院

Method for constructing MRFFT1 cell

ActiveCN110093374AStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsT cellIn vivo
The invention relates to a method for constructing MRFFT1 cells. The method comprises the following steps of: screening out a mutant polypeptide through antigen epitope prediction, connecting and synthesizing a mutant polypeptide expression gene sequence; and meanwhile, constructing an MVA virus vector, packaging MVA virus, transfecting APC cells, completing the modification of specific MV cells,co-culturing PBMC separated from peripheral blood with the modified specific MV cells in vitro, screening out effective polypeptide, modifying common T cells into RFF cells with more accurate killingcapacity through the second impact of accurate effective polypeptide stimulation, performing modification with a TCR-T technology principle, and knocking out immunosuppressive target of the modified Tcells by using a gene editing technology. The method accurately protects specific killing T cells from in-vivo inhibition, and improves the killing ability of T cells to tumor cells.
Owner:BEIJING DCTY BIOTECH CO LTD +1

LFF1 cell

InactiveCN109679916AStrong target specificityLess prone to off-target effectsGenetically modified cellsBlood/immune system cellsAbnormal tissue growthAntigen epitope
The invention belongs to the technical field of biotechnology, and particularly relates to an LFF1 cell and a preparation method thereof. According to the cell, after an antigen-presenting cell is transfected by using lentivirus for expressing antigen epitope peptide, a PBMC (peripheral blood mononuclear cell) is stimulated, then knockout of a suppressive signal molecular target is adopted for protection, and therefore the anti-tumor capacity of a T cell can be effectively improved.
Owner:BEIJING DCTY BIOTECH CO LTD

A method for constructing hafft1 cells

ActiveCN110157745BStrong target specificityLess prone to off-target effectsImmunoglobulin superfamilyGenetically modified cellsTumor antigenT cell
The invention belongs to the field of biotechnology, and in particular relates to a method for constructing HAFFT1 cells. In this method, cells stimulated by small molecule-modified polypeptides are transformed with TCR-T technology, and the transformed T cells are then knocked out immunosuppressive targets, which accurately protects specific killer T cells from in vivo. Inhibition increases the killing power of T cells to tumor cells. The proportion of specific T cells (TCR+) recognizing tumor antigens in cells transformed by the HAFFT1 program was over 80%.
Owner:BEIJING DCTY BIOTECH CO LTD +1